Enceed™ T cell Activation Reagent

GenScript’s Enceed™ T cell Activation Reagent is a biocompatible, non-toxic solution designed for the in vitro activation and expansion of human T cells from PBMCs or enriched T cell populations. Utilizing nanosized particles coated with anti-CD3 and anti-CD28 antibodies, it ensures high-fold expansion with a stable memory phenotype, maintaining high cell viability for enhanced downstream applications.

: High activation and expansion

: Enhanced Memory Phenotype

: Biodegradable and No de-beading

: Global GMP Compliant

Quick Order

Overview All Products Applicatoin Data Resources Related Products Contact Us

Applicatoin Data

Highly Efficient Activation and Expansion

T cell activation requires three signals, including TCR/CD3 and MHC molecule antigen peptide complex, co-stimulatory signals, and cytokines. Enceed™ T cell activation reagent provides the first and second signals, gently activates T cells, and is easy to use. After 48 hours of activation, Enceed™ has a better activation effect than competing products, and the cell expansion multiples are higher after culture.

Activation Biomarkers: CD25⁺ CD69⁺

Figure A. 5x10⁶ T cells were obtained by co-enrichment using CD4&CD8 CytoSinct™ Nanobeads and then activated using Enceed™ T cell Activation and competitior product respectively, followed by expansion in culture medium. The expression of CD25 and CD69 on the surface of T cells was detected 48 hours after activation.

T cell Expansion Assay

Figure B. T cells were stained with CFSE before activation. Seven days after activation, the CFSE signal was detected to demonstrate the expansion status of T cells.

Figure C. The number of activated T cells was monitored. On day 17, Enceed™ T cell Activation could expand T cells by nearly 250-fold.
Enhanced Memory Phenotype

Memory T cells have stronger proliferation and immune memory maintenance capabilities than effector T cells, among which memory stem T cells (TSCM) and central memory T cells (TCM) have the greatest potential.

Therefore, a higher proportion of memory T cells in the final CAR-T cell product may improve clinical efficacy.

Figure D. T cell memory phenotype were examined on days 12 and 17 after activation.